Financial Performance - For the year ended December 31, 2025, SCYNEXIS reported total revenue of $20.6 million, a significant increase from $3.7 million in 2024, primarily due to the GSK license agreement [8] - The company recognized a cumulative catch-up of $17.2 million in license agreement revenue associated with the Binding 2025 MOU with GSK [8] - Research and development expenses decreased to $22.3 million in 2025 from $26.4 million in 2024, a reduction of 15.6% [9] - Selling, general and administrative expenses slightly decreased to $14.4 million in 2025 from $14.5 million in 2024 [10] - The net loss for 2025 was $8.6 million, compared to a net loss of $21.3 million in 2024, indicating improved financial performance [18] Cash Position - As of December 31, 2025, SCYNEXIS had cash, cash equivalents, and investments totaling $56.3 million, down from $75.1 million in 2024 [12] - The company received a one-time non-refundable payment of $24.8 million from GSK in Q4 2025, extending its cash runway for more than two years [5][12] Product Development - SCYNEXIS is advancing its second-generation fungicide, SCY-247, with the first patient dosed in a Phase 1 study of the intravenous formulation, and topline data expected in the second half of 2026 [5][6] - The company plans to initiate an expanded access program for SCY-247 in the first half of 2026 to address patient needs for alternative antifungal therapies [5][6] - The FDA granted SCY-247 Qualified Infectious Disease Product (QIDP) and Fast Track Designations, which may facilitate its development and approval process [6] Strategic Partnerships - SCYNEXIS completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application to GSK, which is committed to relaunching the product [6] - Following the relaunch of BREXAFEMME, SCYNEXIS could receive up to $145.5 million in annual net sales milestones and low to mid-single digit royalties [6] Research Initiatives - A novel series of antifungal compounds from SCYNEXIS' proprietary triterpenoid antifungal platform received funding through a federal grant, establishing a Center of Excellence in Translational Research [7]